Login
$IMRX
$3.52 -$0.19 (5.12%) Live

$IMRX SEC Filings

Filed On Filing
09 Nov 2026 Form 4: Bogle Grant C., Director

Granted 66,700 Stock Option

09 Nov 2026 Form 3: Bogle Grant C., Director

No securities owned

09 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation

On November 9, 2026, the Board of Directors (the "Board") of Immuneering Corporation (the “Company”) appointed Grant C. Bogle, MBA, to serve as a member of the Company's Board as a Class III Director. Mr. Bogle will receive compensation ...

29 Oct 2026 10-Q
29 Oct 2026 8-K: Results of Operations and Financial Condition

- Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected -

05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported ...

28 Jul 2026 SCHEDULE 13G
17 Jul 2026 Form 4: Gengos Andrew, Chief Financial Officer

Granted 650,000 Stock Option

16 Jul 2026 Form 3: Gengos Andrew, Chief Financial Officer

Holds 225,000 shares of Class A Common Stock

24 Jun 2026 Form 4: Zeskind Benjamin J., Director

Bought 2,400 shares ($10.9K)

16 Jun 2026 Form 4: Hall Brett Matthew, CHIEF SCIENTIFIC OFFICER

Bought 6,035 shares ($25K)

15 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

On June 11, 2026, the Board of Directors (the “Board”) of Immuneering Corporation (the “Company”) appointed Andrew Gengos as the Chief Financial Officer and Treasurer of the Company, to become effective on the commencement of his employm...

11 Jun 2026 Form 4: Schall Thomas J., Director

Granted 33,350 Stock Option

11 Jun 2026 Form 4: Hausman Diana, Director

Granted 33,350 Stock Option

11 Jun 2026 Form 4: Carpenter Robert J, Director

Granted 33,350 Stock Option

11 Jun 2026 Form 4: Keating Laurie, Director

Granted 33,350 Stock Option

11 Jun 2026 Form 4: Feinberg Peter, Director

Granted 33,350 Stock Option

11 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 11, 2026, Immuneering Corporation (the “Company”) held its Annual Meeting of Stockholders. A total of 44,495,059 shares of the Company’s Class A common stock were present in person or represented by proxy at the meeting, represen...

01 Jun 2026 8-K: Other Events

On June 1, 2026, Immuneering Corporation (the "Company") announced updated data from its ongoing Phase 2a clinical trial evaluating atebimetinib (formerly known as IMM-1-104), a once-daily oral mitogen-activated protein kinase kinase (or...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support